

A23

40. (Once Amended) A compound of the formula  
FLApYTGLSTRNQETpYATH-NH<sub>2</sub> (SEQ ID NO: 21),  
FLpYpYpYIE-NH<sub>2</sub> (SEQ ID NO: 22), or  
FLGpYNELNLGRREEpYDVL-NH<sub>2</sub> (SEQ ID NO: 23),

wherein FL represents a luminophore and p represents a phosphate group.

As required by 37 C.F.R. § 1.121, applicants have provided a separate, marked-up version of the amended specification and claims, showing the changes relative to the previous version of the specification claims (attached).

#### REMARKS

Applicants received a "Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures" dated August 31, 2001 (copy enclosed). Applicants respond as follows:

1. Applicants hereby provide an initial computer readable form (CRF) copy of the appropriate "Sequence Listing" on diskette (enclosed).
2. Applicants hereby provide an initial paper copy of the "Sequence Listing" (enclosed).
3. Applicants requested that the specification be amended to enter the contents of the "Sequence Listing" into the specification, as set forth above under AMENDMENT.
4. Applicants hereby state that the content of the paper and computer readable copies of the "Sequence Listing" are the same, and that they include no new matter.

Applicants take this opportunity to request two additional amendments, set forth above under AMENDMENT. First, Applicants request that the specification and claims be amended appropriately to identify each peptide sequence of the instant application with respect to the "Sequence Listing." Second, Applicants also request that the specification be amended to add the appropriate serial numbers to the references to various other patent applications contained therein.

In summary, Applicants have provided a computer readable copy of the "Sequence Listing," a paper copy of the "Sequence Listing" and an amendment directing its entry into the specification, and a statement that the content of the two copies is the same and includes no new matter. Applicants therefore suggest that they have fully complied with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

If the Examiner has any questions, or if a telephone interview would in any way advance prosecution of this application, the Examiner is urged to contact the undersigned attorney.


CERTIFICATE OF MAILING

I hereby certify that this correspondence, the diskette with Sequence Listing, and a paper copy of the Sequence Listing are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on October 1, 2001.

  
Shannon R. Verboort

Respectfully submitted,

KOLISCH, HARTWELL, DICKINSON,  
McCORMACK & HEUSER

  
James R. Abney  
Registration No. 42,253  
520 S.W. Yamhill Street, Suite 200  
Portland, Oregon 97204  
Telephone: (503) 224-6655  
Facsimile: (503) 295-6679  
Attorney for Applicant

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

The specification has been amended as follows (material to be inserted is in **bold and underline**, material to be deleted is in ~~[brackets and strikeout]~~):

The paragraph at page 1, lines 4-13 is amended as follows:

This application is based upon and claims priority from the following patent applications, each of which is incorporated herein by reference: U.S. Patent Application Serial No. 08/929,09, filed September 15, 1997; and PCT Patent Application Serial No. **PCT/US00/16025** ~~[\_\_\_\_\_]~~, filed June 9, 2000, entitled *Phosphorylation Assays*, of inventors Wei Huang, Merl F. Hoekstra, Sandra K. Lee, Nicholas Cairns, Lawrence M. Kauvar, and J. Richard Sportsman, which in turn claims priority from U.S. Provisional Patent Applications Serial Nos. 60/138,311, filed June 9, 1999; Serial No. 60/138,438, filed June 10, 1999; and Serial No. 60/200,594, filed April 28, 2000; and from U.S. Patent Application Serial No. 09/349,733, filed July 8, 1999, which in turn claims priority from U.S. Provisional Patent Application Serial No. 60/092,203, filed July 9, 1998.

The paragraph at page 2, lines 1-14 is amended as follows:

This application also incorporates by reference the following PCT patent applications: Serial No. PCT/US99/01656, filed January 25, 1999; Serial No. PCT/US99/03678, filed February 19, 1999; Serial No. PCT/US99/08410, filed April 16, 1999; Serial

No. PCT/US99/16057, filed July 15, 1999; Serial No. PCT/US99/16453, filed July 21, 1999; Serial No. PCT/US99/16621, filed July 23, 1999; Serial No. PCT/US99/16286, filed July 26, 1999; Serial No. PCT/US99/16287, filed July 26, 1999; Serial No. PCT/US99/24707, filed October 19, 1999; Serial No. PCT/US00/00895, filed January 14, 2000; Serial No. PCT/US00/03589, filed February 11, 2000; Serial No. PCT/US00/04543, filed February 22, 2000; Serial No. PCT/US00/06841, filed March 15, 2000; Serial No. PCT/US00/12277, filed May 3, 2000; Serial No. **PCT/US00/15774** [\_\_\_\_], filed June 9, 2000, entitled *Improvements in Luminescence Polarization Assays*, of inventors J. Richard Sportsman and Lawrence M. Kauvar; and Serial No. **PCT/US00/16012** [\_\_\_\_], filed June 9, 2000, entitled *Cell-Signaling Assays*, of inventors J. Richard Sportsman and Lawrence M. Kauvar.

The paragraph at page 2, line 15 to page 3, line 5 is amended as follows:

This application also incorporates by reference the following U.S. provisional patent applications: Serial No. 60/138,737, filed June 11, 1999; Serial No. 60/138,893, filed June 11, 1999; Serial No. 60/142,721, filed July 7, 1999; Serial No. 60/143,185, filed July 9, 1999; Serial No. 60/153,251, filed September 10, 1999; Serial No. 60/164,633, filed November 10, 1999; 60/165,813, filed November 16, 1999; Serial No. 60/167,301, filed November 24, 1999; Serial No. 60/167,463, filed November 24, 1999; Serial No. 60/178,026, filed January 26, 2000; Serial No. 60/182,036, filed February 11, 2000; Serial No. 60/182,419, filed February 14, 2000; Serial No. 60/184,719, filed February 24, 2000; Serial No. 60/184,924, filed February 25, 2000; Serial No. 60/190,265, filed March 17, 2000; Serial No. 60/191,890, filed March 23, 2000; Serial No. 60/193,586, filed March 30, 2000;

Serial No. 60/197,324, filed April 14, 2000; Serial No. 60/200,530, filed April 27, 2000; and Serial No. 60/202,087 [\_\_\_\_], filed May 4, 2000, entitled *Nucleic Acid Detection Methods*, of inventors Susan S. Kalman and Enal S. Ravi.

The paragraph at page 28, lines 1-6 is amended as follows:

The peptide to be coupled to luminescent label was of the formula GEEGYMPMGK (SEQ ID NO: 1), where the tyrosine residue is chemically phosphorylated, and the C-terminal lysine is derivatized on the  $\epsilon$  amino group with a biotin. The derivatization with biotin is irrelevant to the claimed assay. The tracer form of this peptide was prepared by coupling fluorescein to the amino terminus by reaction with fluorescein isothiocyanate (FITC).

The paragraph at page 28, lines 10-16 is amended as follows:

The single-tube reader is a more sensitive instrument, and can use less tracer. In the FPM-1, the tracer form of the peptide (GEEGYMPMGK; SEQ ID NO: 1) coupled with fluorescein to the amino terminus was used at 0.3 nM. To transfer this technology to multiple samples, the assay was transferred to a 96-well format. In doing so, the sensitivity of the instrument is less, and as a result more tracer is required to give adequate signal. We were able to see 7.5 and 15 nM of the tracer form of the peptide coupled with fluorescein. For the simpler tracer, FL-phosphotyramine, we had to use 35 nM of the tracer.

The paragraph at page 29, lines 16-21 is amended as follows:

Several peptides were used as substrates for phosphorylation. These peptides were:

KS2: biotin-EGPWLEEEEEAYGWMDF-amide (**SEQ ID NO: 2;**

Boehringer-Manheim Catalog No. 1768719);

D-peptide: DYMTMQIG (**SEQ ID NO: 3;**

S-peptide: SRGDYMTMQIG (**SEQ ID NO: 4).**

The paragraph at page 34, line 11 to page 35, line 7 is amended as follows:

The protein substrate may include a generic substrate capable of being phosphorylated by a variety of S/T kinases. Preferred generic substrates may include histone type III-ss, human/bovine myelin basic protein (MBP), and fragments of MBP including all or part of amino acids 4-14. The lattermost substrate has the following sequence:

**EKRPSQRSKYL** (**SEQ ID NO: 5)**

Here (and throughout the application), S is the one-letter abbreviation for serine, T is the one-letter abbreviation for threonine, and E, K, R, . . . are the one-letter abbreviations for other amino acids, as specified in the Appendix. Here, S and T are underlined so that the location(s) of potential phosphorylation sites may be more easily identified. Preferred substrates also may include serine and/or threonine amino acids followed in the C-terminal direction by a proline residue, particularly immediately after (i.e., within one amino acid) of the serine or threonine. Preferred substrates also may include amino acid sequences having one or more serine and/or threonine amino acids, enriched for several amino acids to one or both sides of at least one serine and/or threonine by basic amino acids, such as lysine,

arginine, and histidine, particularly within about three amino acids in the C-terminal direction. Basic amino acids, including lysine, arginine, and histidine, generally are positively charged under physiological conditions. These substrates are preferred because they may have enhanced recognition by kinase enzymes.

The paragraph at page 36, line 6 to page 37, line 2 is amended as follows:

Preferred specific binding partners include immunological specific binding partners, such as antibodies. In particular, preferred specific binding partners include antibodies against unphosphorylated or phosphorylated forms of the preferred protein substrates listed above, including antibodies against the following phosphorylated MBP fragments:

**EKRPPSRSKYL (SEQ ID NO: 6)**

**EKRPSQRPSYL (SEQ ID NO: 7)**

**EKRPPSRPSYL (SEQ ID NO: 8)**

Here, a “p” is used to denote phosphorylation of the subsequent amino acid. Preferred specific binding partners also include antibodies against the following phosphorylated peptides:

**KRREILSRPPSYRK (SEQ ID NO: 9)**

**KHFPQFPSSAS (SEQ ID NO: 10)**

**pSPELERLIIQC (SEQ ID NO: 11)**

**GSPSVRCSPMPs (SEQ ID NO: 12)**

**RSRHSPPSYAGT (SEQ ID NO: 13)**

**LpTPLK (SEQ ID NO: 14)**

**FpTPLQ (SEQ ID NO: 15)**

**RKRpTLRRL (SEQ ID NO: 16)**

**LRRApSLG (SEQ ID NO: 17)**

**KKLNRTLpSVASL (SEQ ID NO: 18)**

**RPRAApTF-NH<sub>2</sub> (SEQ ID NO: 19)**

**LRRApSLG-NH<sub>2</sub> (SEQ ID NO: 20)**



The lattermost two peptides are amidated at the C-terminal, which may act to stabilize the peptides.

The paragraph at page 46, lines 3-13 is amended as follows:

In still another aspect, the invention is directed to specifically designed peptides that show enhanced affinity for binding to the 4G10 antibody, which is directed to phosphorylated tyrosine. Phosphorylated tyrosine is an indicator of an activated form of the insulin receptor and many other receptors such as EGF-receptor, and IGF-1 receptor, as well as nonreceptor tyrosine kinases such as src, fyn and many others known in the art. These peptides are of the formula

FL-A-pY-TGLSTRNQET-pY-ATH-NH<sub>2</sub> **(SEQ ID NO: 21)**

FL-pY-pY-pY-IE-NH<sub>2</sub> **(SEQ ID NO: 22)**

FL-G-pY-NELNLGRREE-pY-DVL-NH<sub>2</sub> **(SEQ ID NO: 23)**

Here, Y is the one-letter abbreviation for tyrosine, pY is phosphorylated tyrosine, and A, T, G . . . are one-letter abbreviations for other amino acids, as specified in the Appendix.

The paragraph at page 50, lines 14-16 is amended as follows:

The macromolecule loaded with Ga<sup>3+</sup> (MM-Ga) was tested for the binding of the following di-(phosphotyrosine) peptide fluorescein-labeled tracer, denoted tyrosine kinase 1 (TK-1) tracer: FL-A-pY-TGLSTRNQET-pY-ATH-NH<sub>2</sub> **(SEQ ID NO: 21)**.

The paragraph at page 51, lines 7-9 is amended as follows:

The macromolecule loaded with  $\text{Ga}^{3+}$  (MM-Ga) also was tested for the binding of the following fluorescein-labeled monophosphoserine peptide tracer, denoted serine/threonine kinase 1 (STK-1) tracer: FL-RFARKG-pS-LRQKNV (**SEQ ID NO: 24**).

The paragraph at page 51, line 18 to page 52, line 2 is amended as follows:

We demonstrated the specificity of the binding between phosphorylated peptide and a macromolecule activated with Ga (III) metal ion (MM-Ga) and its potential in the development of generic kinase assays. The materials included cAMP-dependent protein kinase A (PKA, from Promega) as the enzyme and fluorescein-labeled Kemptide (fluo-Leu-Arg-Arg-Ala-Ser-Leu-Gly; **SEQ ID NO: 25**) as the substrate.

The paragraph at page 55, line 17 to page 56, line 3 is amended as follows:

This example shows assays for integrated cell signaling mechanisms. Specifically, the assays described here for kinase and phosphatase enzymes may be performed in combination with the assays for cyclic nucleotides and GTP-binding proteins described in PCT Patent Application Serial No. **PCT/US00/16012** [—], filed June 9, 2000, entitled *Cell-Signaling Assays*, of inventors J. Richard Sportsman and Lawrence M. Kauvar, which is incorporated herein by reference. Such combination assays permit study of signaling mechanisms involving multiple pathways.

The paragraph at page 64, line 2-21, is amended as follows:

13. The method of paragraph 1, wherein the peptide is selected from the group consisting of

ApYTGLSTRNQETpYATH-NH<sub>2</sub> (SEQ ID NO: 26),

pYpYpYIE-NH<sub>2</sub> (SEQ ID NO: 27),

GpYNELNLGRREEpYDVL-NH<sub>2</sub> (SEQ ID NO: 28),

EKRppSRSKYL (SEQ ID NO: 29),

EKRPSQRpSYL (SEQ ID NO: 30),

EKRppSRpSYL (SEQ ID NO: 8),

KRREILSRRPpSYRK (SEQ ID NO: 9),

KHFPQFpSYSAS (SEQ ID NO: 10),

pSPELERLIIQC (SEQ ID NO: 11),

GSPSVRCSpSMpS (SEQ ID NO: 12),

RSRHSpSYPAGT (SEQ ID NO: 13),

LpTPLK (SEQ ID NO: 14),

FpTPLQ (SEQ ID NO: 15),

RKRpTLRRL (SEQ ID NO: 16),

LRRApSLG (SEQ ID NO: 17),

KKLNRTLpSVASL (SEQ ID NO: 18),

RPRAApTF-NH<sub>2</sub> (SEQ ID NO: 19) and

LRRApSLG-NH<sub>2</sub> (SEQ ID NO: 20).

The paragraph at page 66, lines 17-19 is amended as follows:

24. The method of paragraph 23, wherein the modified form of the substrate is the phosphorylated form of biotin-EGPWLEEEEEAYGWMDf-amide (KS2-peptide; SEQ ID NO: 2), DYMTMQIG (D-peptide; SEQ ID NO: 3), or SRGDYMTMQIG (S-peptide; SEQ ID NO: 4).

The paragraph at page 67, lines 7-20 is amended as follows:

27. A method to determine the presence and amount of a posttranslationally modified protein or peptide comprising, contacting a sample containing said posttranslationally modified protein or peptide with a luminescence tracer and a specific binding partner, wherein said tracer and said posttranslationally modified protein or peptide compete for binding to said partner, and wherein, when said tracer is bound to said partner, its luminescence polarization is changed from that of the tracer in unbound form, followed by measuring the luminescence polarization in the sample, whereby a change in the luminescence polarization to more closely approximate that of the tracer in unbound form is a measure of the presence or amount of said posttranslationally modified protein or peptide, wherein the posttranslational modification results in a posttranslationally modified substrate from an enzyme catalyzed reaction of a protein or peptide substrate that is catalyzed by the insulin receptor cytoplasmic kinase domain (IR-CKD) or IGF-1r cytoplasmic kinase domain (IGF-1r-CKD), and wherein the tracer is a fluorescein conjugate of the peptide GEEGYMPMGK (SEQ ID NO: 1) or N-acetyl-O-phosphotyramine.

Applicants have amended the specification by inserting the attached “Sequence Listing” immediately prior to the claims.

#### IN THE CLAIMS

Claims 16, 30, 32, 33, 34, 38, and 40 are amended as follows: (material to be inserted is in **bold and underline**, material to be deleted is in [~~brackets and strikeout~~):

16. (Once Amended) The method of claim 1, wherein the peptide is selected from the group consisting of

EKR<sub>P</sub>SRSKYL (**SEQ ID NO: 29**),  
EKR<sub>P</sub>SQR<sub>P</sub>SYL (**SEQ ID NO: 30**),  
EKR<sub>P</sub>SR<sub>P</sub>SYL (**SEQ ID NO: 8**),  
KRREILSR<sub>P</sub>SYRK (**SEQ ID NO: 9**),  
KHFPQF<sub>P</sub>SYSAS (**SEQ ID NO: 10**),  
pSPELERLIIQC (**SEQ ID NO: 11**),  
GSPSVRC<sub>S</sub>pSM<sub>P</sub>S (**SEQ ID NO: 12**),  
RSRH<sub>S</sub>pSYAGT (**SEQ ID NO: 13**),  
L<sub>P</sub>TPLK (**SEQ ID NO: 14**),  
F<sub>P</sub>TPLQ (**SEQ ID NO: 15**),  
RKR<sub>P</sub>TLRRL (**SEQ ID NO: 16**),  
LRR<sub>A</sub>pSLG (**SEQ ID NO: 17**),

KKLNRTLpSVASL (SEQ ID NO: 18),

RPRAApTF-NH<sub>2</sub> (SEQ ID NO: 19), and

LRRApSLG-NH<sub>2</sub> (SEQ ID NO: 20).

30. (Once Amended) A kinase substrate comprising  
a luminophore, and  
a peptide sequence selected from the group consisting of

AYTGLSTRNQETYATH-NH<sub>2</sub> (SEQ ID NO: 31),

YYYIE-NH<sub>2</sub> (SEQ ID NO: 32),

GYNELNLGRREEYDVL-NH<sub>2</sub> (SEQ ID NO: 33),

EKRPSRSKYL (SEQ ID NO: 34),

EKRPSQRSYL (SEQ ID NO: 35),

EKRPSRSYL (SEQ ID NO: 36),

KRREILSRRPSYRK (SEQ ID NO: 37),

KHFPQFSYSAS (SEQ ID NO: 38),

SPELERLIIQC (SEQ ID NO: 39),

GSPSVRCSSMS (SEQ ID NO: 40),

RSRHSSYPAGT (SEQ ID NO: 41),

LTPLK (SEQ ID NO: 42),

FTPLQ (SEQ ID NO: 43),

RKRTLRL (SEQ ID NO: 44),

LRRASLG (SEQ ID NO: 45),

KKLNRTLSTVASL (SEQ ID NO: 46),

RPRAATF-NH<sub>2</sub> (SEQ ID NO: 47), and

LRRASLG-NH<sub>2</sub> (SEQ ID NO: 48).

32. (Once Amended) The substrate of claim 30, wherein the substrate can be phosphorylated by tyrosine kinase, the peptide having an amino acid sequence selected from the group consisting of

AYTGLSTRNQETYATH-NH<sub>2</sub> (SEQ ID NO: 31),

YYYIE-NH<sub>2</sub> (SEQ ID NO: 32), and

GYNELNLGRREEYDVL-NH<sub>2</sub> (SEQ ID NO: 33).

33. (Once Amended) The substrate of claim 30, wherein the substrate can be phosphorylated by a serine/threonine kinase, the peptide being selected from the group consisting of

EKRPSRSKYL (SEQ ID NO: 34),

EKRPSQRSYL (SEQ ID NO: 35),

EKRPSRSYL (SEQ ID NO: 36),

KRREILSRRPSYRK (SEQ ID NO: 37),

KHFPQFSYSAS (SEQ ID NO: 38),

SPELERLIIQC (SEQ ID NO: 39),

GSPSVRCSSMS (SEQ ID NO: 40),

RSRHSSYPAGT (SEQ ID NO: 41),

LTPLK (SEQ ID NO: 42),

FTPLQ (SEQ ID NO: 43),

RKRTLRL (SEQ ID NO: 44),

LRRASLG (SEQ ID NO: 45),

KKLNRTLSVASL (SEQ ID NO: 46),

RPRAATF-NH<sub>2</sub> (SEQ ID NO: 47), and

LRRASLG-NH<sub>2</sub> (SEQ ID NO: 48).

34. (Once Amended) A composition comprising at least one peptide selected from the following group

EKRPPSRSKYL (SEQ ID NO: 29),

EKRPSQRPSYL (SEQ ID NO: 30),

EKRPPSRPSYL (SEQ ID NO: 8),

KRREILSRRPPSYRK (SEQ ID NO: 9),

KHFPQFPSYSAS (SEQ ID NO: 10),

pSPELERLIIQC (SEQ ID NO: 11),

GSPSVRCSpSMpS (SEQ ID NO: 12),

RSRHSpSYPAGT (SEQ ID NO: 13),

LpTPLK (SEQ ID NO: 14),

FpTPLQ (SEQ ID NO: 15),

RKRpTLRL (SEQ ID NO: 16),

LRRApSLG (SEQ ID NO: 17),



KKLNRTLpSVASL (SEQ ID NO: 18),

RPRAApTF-NH<sub>2</sub> (SEQ ID NO: 19), and

LRRApSLG-NH<sub>2</sub> (SEQ ID NO: 20).

38. (Once Amended) The composition of claim 36, the binding partner binds specifically to at least one peptide selected from the following group

EKRPPSRSKYL (SEQ ID NO: 29),

EKRPSQRpSYL (SEQ ID NO: 30),

EKRPPSRpSYL (SEQ ID NO: 8),

KRREILSRRPpSYRK (SEQ ID NO: 9),

KHFPQFpSYSAS (SEQ ID NO: 10),

pSPELERLIIQC (SEQ ID NO: 11),

GSPSVRCSpSMpS (SEQ ID NO: 12),

RSRHSpSYPAGT (SEQ ID NO: 13),

LpTPLK (SEQ ID NO: 14),

FpTPLQ (SEQ ID NO: 15),

RKRpTLRRL (SEQ ID NO: 16),

LRRApSLG (SEQ ID NO: 17),

KKLNRTLpSVASL (SEQ ID NO: 18),

RPRAApTF-NH<sub>2</sub> (SEQ ID NO: 19), and

LRRApSLG-NH<sub>2</sub> (SEQ ID NO: 20).

40. (Once Amended) A compound of the formula
- FLApYTGLSTRNQETpYATH-NH<sub>2</sub> (SEQ ID NO: 21),
- FLpYpYpYIE-NH<sub>2</sub> (SEQ ID NO: 22), or
- FLGpYNELNLGRREEpYDVL-NH<sub>2</sub> (SEQ ID NO: 23),
- wherein FL represents a luminophore and p represents a phosphate group.